Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
2.530
+0.040 (1.61%)
At close: Oct 8, 2025, 4:00 PM EDT
2.580
+0.050 (1.98%)
After-hours: Oct 8, 2025, 7:12 PM EDT

Alzamend Neuro Income Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jul '25 Apr '25 Apr '24 Apr '23 Apr '22 Apr '21 2016 - 2020
Selling, General & Admin
3.293.083.487.427.123.64
Upgrade
Research & Development
2.951.416.467.455.21.31
Upgrade
Operating Expenses
6.234.59.9414.8712.324.95
Upgrade
Operating Income
-6.23-4.5-9.94-14.87-12.32-4.95
Upgrade
Interest Expense
-0.01-0.02-0.01-0.01-0.05-0.16
Upgrade
Interest & Investment Income
-----0
Upgrade
EBT Excluding Unusual Items
-6.24-4.51-9.95-14.88-12.37-5.11
Upgrade
Other Unusual Items
----00.06
Upgrade
Pretax Income
-6.24-4.51-9.95-14.88-12.36-5.05
Upgrade
Net Income
-6.24-4.51-9.95-14.88-12.36-5.05
Upgrade
Preferred Dividends & Other Adjustments
0.590.59----
Upgrade
Net Income to Common
-6.83-5.11-9.95-14.88-12.36-5.05
Upgrade
Shares Outstanding (Basic)
100000
Upgrade
Shares Outstanding (Diluted)
100000
Upgrade
Shares Change (YoY)
1121.34%499.67%4.07%9.45%22.64%1.96%
Upgrade
EPS (Basic)
-7.15-11.32-132.33-205.97-187.31-93.78
Upgrade
EPS (Diluted)
-7.15-11.32-132.33-205.97-187.31-93.78
Upgrade
Free Cash Flow
-8.09-6.87-8.42-8.92-6.72-2.71
Upgrade
Free Cash Flow Per Share
-8.46-15.24-111.97-123.53-101.83-50.40
Upgrade
EBITDA
-6.17-4.45-9.89-14.85-12.32-
Upgrade
D&A For EBITDA
0.070.050.050.020-
Upgrade
EBIT
-6.23-4.5-9.94-14.87-12.32-4.95
Upgrade
Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q